Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zelira Therapeutics ( (AU:ZLD) ) has issued an update.
Zelira Therapeutics has secured a $650,000 R&D loan facility from RH Capital Finance Co., LLC, which is backed by the anticipated R&D Tax incentive rebate for FY25. This non-dilutive funding will enhance Zelira’s short-term cash position, supporting the advancement of the HOPE SPV clinical trial and general working capital needs. The agreement is expected to bolster Zelira’s operational capabilities and strengthen its industry positioning by enabling further research and development activities.
More about Zelira Therapeutics
Zelira Therapeutics is a global leader in cannabinoid-based biopharmaceuticals, focusing on the development and commercialization of products derived from cannabinoids. The company is engaged in research and development initiatives aimed at advancing clinical trials and enhancing its market position within the biopharmaceutical industry.
Average Trading Volume: 4,989
Technical Sentiment Signal: Sell
Current Market Cap: A$4.88M
See more data about ZLD stock on TipRanks’ Stock Analysis page.